# Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients

> **NCT02877082** · PHASE2 · TERMINATED · sponsor: **Emory University** · enrollment: 5 (actual)

## Conditions studied

- Acute Leukemia
- Chronic Lymphocytic Leukemia
- Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Diffuse Large B-Cell Lymphoma
- Follicular Lymphoma
- Graft Versus Host Disease
- Mantle Cell Lymphoma
- Marginal Zone Lymphoma
- Myelodysplastic Syndrome
- Myelofibrosis
- Myeloproliferative Neoplasm
- Small Lymphocytic Lymphoma

## Interventions

- **BIOLOGICAL:** Thymoglobulin
- **DRUG:** Bortezomib
- **DRUG:** Tacrolimus

## Key facts

- **NCT ID:** NCT02877082
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-09
- **Primary completion:** 2017-07
- **Final completion:** 2017-07
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2018-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02877082

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02877082, "Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT02877082. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*